1 active not recruiting, 1 completed. 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Active not recruiting 1, Completed 1 |
Follow CIT-013 medium dose: new trials by email Literature Review of CIT-013 medium dose trials Research Report on CIT-013 medium dose
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study With CIT-013 in HS Patients CIT-013 high dose, CIT-013 medium dose, Placebo - Hidradenitis Suppurativa (HS) | Phase 2 | Active not recruiting | Citryll BV | 108 | 2025-10-31 | 2026-10-19 |
| A Study With CIT-013 in RA Patients CIT-013 low dose, CIT-013 high dose, Placebo - Rheumatoid Arthritis | Phase 2 | Completed | Citryll BV | 96 | 2025-07-29 | 2026-10-19 |
Arthritis, Rheumatoid (1) · Hidradenitis Suppurativa (1)
Citryll BV (2)
Germany (2) · Netherlands (2) · Poland (2) · Spain (2) · Belgium (1) · Canada (1) · United Kingdom (1)
Maarten Kraan (2)